David P. Carbone

David P. Carbone's research focuses on lung cancer, particularly non-small-cell lung cancer (NSCLC), with an emphasis on immunotherapy, drug resistance mechanisms, molecular staging, and clinical trials of new treatments including checkpoint inhibitors and antibody-drug conjugates. Much of the work involves large multi-institutional clinical trials and translational studies linking tumor biology (e.g., gene mutations like KEAP1/STK11, EGFR, MET) to treatment outcomes. This research is highly clinically oriented, aiming to improve treatment strategies and patient selection for lung cancer therapies.

Publication output was fairly steady from 2017-2022 (around 37-66 per year), spiked sharply in 2023 (239 publications), and has since returned to a level (45-55) somewhat higher than the pre-2023 baseline.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026